Sickle cell disease is a genetic disease that almost exclusively affects non-European populations. The number of birth screenings is used to measure the Great Replacement. Already, in 2018, the State had decided to no longer communicate the number of tests.
The State is now going further… by generalizing the tests to all births, whereas this is useless for the children of European parents.
The High Authority for Health (HAS) gave this November 15 a favorable opinion on the extension of screening for sickle cell disease to all French newborns. This opinion was written following a referral from the Directorate General for Health (DGS). This opinion echoes the amendment to the Social Security financing bill presented on October 27 by the executive. The latter provides for a three-year national experiment in generalized screening.
“At the latest six months before the end of the experiment, the government will submit an evaluation report to Parliament, which will decide in particular on the relevance of a generalization”.
Sickle cell disease has an incidence of one birth in 1,323 in 2020, a constant increase since 2010, which makes it the most common genetic disease in France. In its previous opinion in 2014, the HAS concluded that there was no data showing the need for generalized screening for all newborns. More than three out of four children participate in screening in Île-de-France against barely one in two nationally.